Sarcoma
Circulating Tumor DNA in Heterogeneous Mesenchymal Malignancies
Clinical Overview
Sarcomas represent a heterogeneous group of over 70 histologic subtypes arising from mesenchymal tissues, including bone, soft tissue, and visceral organs. This extreme heterogeneity profoundly impacts ctDNA testing performance, with detection rates and clinical utility varying substantially across subtypes. Unlike epithelial malignancies, many sarcomas are "low-shedder" tumor types, presenting unique challenges for liquid biopsy applications.
Clinical Impact: ctDNA testing in sarcoma serves two distinct clinical purposes: minimal residual disease (MRD) detection for prognostication and surveillance, and comprehensive genotyping for identification of actionable therapeutic targets. Performance varies dramatically by subtype, with GIST and dedifferentiated liposarcoma demonstrating superior detection compared to leiomyosarcoma and other subtypes.
Key Subtype-Specific Characteristics:
- GIST: 70-80% harbor KIT mutations (exons 11/9); favorable ctDNA detection rates
- Liposarcoma: MDM2 amplification; higher ctDNA shedding, particularly dedifferentiated subtype
- Leiomyosarcoma: TP53, RB1 mutations; lower ctDNA detection rates; limited targeted options
- Synovial sarcoma: SS18-SSX fusion; investigational targeted therapies
- NTRK fusion-positive sarcomas: Rare but highly actionable with TRK inhibitors
Understanding ctDNA Testing in Sarcoma
Challenges Unique to Sarcoma ctDNA Testing
Low-Shedder Tumor Biology:
- Lower ctDNA release: Many sarcomas shed less DNA into circulation compared to carcinomas
- Tumor location impact: Retroperitoneal and intramuscular tumors may have limited vascular access
- Slow growth rates: Well-differentiated subtypes release minimal ctDNA
- Histologic diversity: >70 subtypes with distinct molecular profiles require subtype-specific panels
ctDNA Detection Performance in Sarcoma
Recent Large-Scale Data (Stanford/Natera, ASCO 2024-2025):
- Overall MRD sensitivity: 89% with tumor-informed assay (>200 patients, >2,100 samples; largest sarcoma ctDNA study to date)
- Specificity: 100% across subtypes tested
- Leiomyosarcoma sensitivity: 93% with tumor-informed assay (Signatera)
- Lead time: Median 64.8 days (~2 months) before imaging-detected recurrence (ASCO 2024 multicenter study)
- ctDNA detected at or before radiologic recurrence in 47% of relapsing localized STS patients (n=19 evaluable)
Important caveats:
- Performance varies by assay technology and sarcoma subtype
- Translocation-driven sarcomas (synovial, myxoid liposarcoma) may have lower detection with standard panels due to stable genomes
- Low-grade and well-differentiated subtypes shed minimal ctDNA
- Prospective validation in large randomized trials is still lacking for most subtypes
Key clinical applications:
- Post-surgical MRD detection in high-grade sarcomas
- Monitoring during adjuvant/neoadjuvant therapy
- Early relapse detection in high-risk subtypes
Clinical Decision Points for Sarcoma Subtypes
When to Use Each Approach
| Clinical Scenario | Recommended Approach | Rationale |
|---|---|---|
| Post-surgical MRD (high-grade sarcoma) | Tumor-informed | Maximum sensitivity needed; tracks patient-specific mutations |
| GIST genotyping for treatment selection | Either approach | KIT mutations detectable with or without baseline |
| NTRK fusion screening | Tumor-agnostic (RNA-based) | Rare fusions require comprehensive fusion panels |
| Imatinib resistance monitoring in GIST | Either approach | Secondary KIT mutations can emerge during treatment |
| Liposarcoma MDM2 amplification | Either approach | Copy number alterations detectable by both methods |
LIQOMICS Testing Solutions for Sarcoma
CancerVista offers tumor-informed ctDNA testing for sarcoma enabling MRD detection after surgery and therapy response monitoring.
Key Features:
- Baseline profiling from tissue biopsy or plasma sample
- Ultra-high sensitivity for MRD detection
- Tracks patient-specific mutations for specific and precise MRD quantification
- Enables ctDNA-guided therapy decisions
- Allows early relapse detection during surveillance
Minimal Residual Disease Detection: Clinical Utility by Subtype
Prognostic Value Varies with Sarcoma Type
Overview: MRD detection in sarcoma demonstrates subtype-specific performance, with GIST and dedifferentiated liposarcoma showing superior detection rates compared to leiomyosarcoma and other subtypes. The heterogeneity of sarcoma biology fundamentally impacts ctDNA shedding and detection sensitivity.
MRD Detection Performance by Subtype
GIST (Gastrointestinal Stromal Tumor):
- ctDNA detection: >90% sensitivity for KIT mutations in advanced disease
- MRD application: Post-surgical monitoring feasible; high detection rates due to recurrent driver mutations
- Lead time: Resistance mutations detected 1-3 months before imaging progression
- Primary utility: Genotyping for treatment selection and resistance monitoring (more established than MRD)
- Clinical context: Favorable ctDNA detection among sarcoma subtypes due to recurrent KIT/PDGFRA mutations
Dedifferentiated Liposarcoma:
- ctDNA detection: Favorable due to MDM2 amplification (>95% prevalence) enabling copy number-based detection
- MRD utility: Post-surgical monitoring feasible; MDM2 amplification facilitates detection
- Key marker: MDM2 amplification detectable via copy number analysis in liquid biopsy
- Clinical utility: Diagnostic confirmation and recurrence monitoring
- Limitation: Specific MRD hazard ratio data from prospective trials not yet available
Leiomyosarcoma:
- ctDNA detection: 93% sensitivity with tumor-informed assay (Signatera, Stanford/Natera 2025); ctDNA kinetics correlated with treatment response in 90% of cases
- Earlier estimates: Lower sensitivity (40-50%) reported with less sensitive assays in smaller studies
- Molecular profile: TP53 (40-60%), RB1 mutations; variable profiles require tumor-informed approach
- Lead time: Median 64.8 days before imaging recurrence (ASCO 2024 multicenter study, predominantly leiomyosarcoma)
- Clinical note: Assay technology significantly impacts detection rates; tumor-informed approaches substantially outperform fixed panels
Synovial Sarcoma:
- Molecular marker: SS18-SSX fusion transcript (>95% of cases)
- Detection method: RNA-based testing may be preferred for fusion detection
- Challenge: Stable genome with fewer structural variants may reduce sensitivity with standard DNA-based panels
- Clinical utility: Fusion-specific monitoring and clinical trial enrollment
Undifferentiated Pleomorphic Sarcoma:
- Challenge: Heterogeneous molecular profiles without recurrent driver mutations
- Approach: Tumor-informed testing essential due to patient-specific mutations
- Clinical utility: Bespoke ctDNA assays can detect MRD but require baseline tissue profiling
Clinical Interpretation Across Subtypes
Key Findings:
- Tumor-informed assays: Overall sensitivity 89%, specificity 100% in the largest study (>200 patients, Stanford/Natera 2025)
- Leiomyosarcoma: 93% sensitivity with tumor-informed assay; ctDNA kinetics correlated with treatment response in 90%
- GIST: High detection rates for KIT/PDGFRA mutations; primary utility is genotyping and resistance monitoring
- Translocation-driven sarcomas: May have lower detection with standard DNA panels; RNA-based approaches may improve performance
- Lead time advantage: Median ~2 months when ctDNA is detectable
- Assay technology critical: Tumor-informed approaches substantially outperform fixed panels in sarcoma
Clinical Significance: MRD detection in sarcoma has advanced substantially, with tumor-informed assays now achieving 89% overall sensitivity (Stanford/Natera 2025, >200 patients). Assay technology is a critical determinant of performance: tumor-informed approaches substantially outperform fixed panels in this molecularly heterogeneous disease. Tissue biopsy remains essential for definitive diagnosis, and ctDNA should be integrated with imaging and clinical assessment. Note: While the largest study to date demonstrates high sensitivity, most data remain from retrospective cohorts; prospective interventional validation is still needed.
Genotyping for Targeted Therapy Selection
Subtype-Specific Molecular Profiling
Overview: Sarcoma genotyping via ctDNA enables identification of actionable mutations and selection of targeted therapies. Unlike MRD detection, genotyping focuses on treatment-guiding alterations rather than prognostication.
GIST: KIT and PDGFRA Mutations
KIT Exon 11 Mutations (60-70% of GIST):
- First-line therapy: Imatinib
- Overall response rate: 54-83%
- Median progression-free survival: 18-24 months
- ctDNA detection: >90% sensitivity for KIT mutations
- Clinical utility: Confirms diagnosis and guides initial therapy
KIT Exon 9 Mutations (10-15% of GIST):
- First-line therapy: Imatinib (higher dose 400mg BID)
- Overall response rate: 48-67% (dose-dependent)
- Clinical implication: Exon 9 mutations predict benefit from dose escalation
- ctDNA utility: Non-invasive mutation detection guides dosing strategy
PDGFRA D842V Mutation (5-10% of GIST):
- Clinical challenge: Primary resistance to imatinib, sunitinib, regorafenib
- Targeted therapy: Avapritinib
- Overall response rate: 88-91% (NAVIGATOR trial; 88% initial report, 91% long-term data)
- Median progression-free survival: 24 months
- ctDNA detection: Identifies imatinib-resistant genotype pre-treatment
- Clinical impact: Avoids futile imatinib therapy and selects appropriate first-line treatment
Secondary KIT Mutations (Resistance Monitoring):
- Context: Emerge in 30-50% of GIST during imatinib therapy
- Common resistance mutations: KIT exons 13, 14, 17, 18
- Clinical action: Switch to sunitinib or regorafenib based on mutation pattern
- ctDNA monitoring: Serial testing every 3-4 months during therapy
- Lead time advantage: Detects resistance 1-3 months before imaging progression
Liposarcoma: MDM2 Amplification and Targeted Approaches
MDM2 Amplification (Well-Differentiated/Dedifferentiated Liposarcoma):
- Prevalence: >95% of dedifferentiated liposarcoma
- Diagnostic utility: Differentiates from other high-grade sarcomas
- ctDNA detection: Copy number analysis via liquid biopsy
- Targeted therapy: MDM2 inhibitors in clinical trials
- Alrizomadlin: Phase II/III trials ongoing
- Brigimadlin: Early phase studies
- Current limitation: No approved MDM2-targeted therapies; trial enrollment recommended
- Future potential: MDM2 amplification may become actionable biomarker
Leiomyosarcoma: Limited Targeted Options
TP53 and RB1 Mutations (40-60% of LMS):
- Clinical challenge: Tumor suppressor mutations are not directly targetable
- Prognostic value: TP53 mutation associated with worse outcomes
- Current approach: Cytotoxic chemotherapy (doxorubicin, gemcitabine/docetaxel)
- Investigational strategies:
- CDK4/6 inhibitors (for RB1 wild-type)
- Synthetic lethality approaches targeting TP53 pathway
- ctDNA utility: Limited therapeutic actionability; primarily prognostic
Synovial Sarcoma: SS18-SSX Fusions
SS18-SSX Fusion Transcript (>95% of Synovial Sarcoma):
- Diagnostic utility: Pathognomonic fusion confirms diagnosis
- Detection method: RNA-based liquid biopsy required for fusion detection
- ctDNA sensitivity: 50-70% for fusion transcript detection in advanced disease
- Targeted therapy: Clinical trials investigating:
- EZH2 inhibitors (tazemetostat)
- HDAC inhibitors
- SS18-SSX peptide vaccines
- Current limitation: No approved fusion-targeted therapies; standard chemotherapy remains first-line
NTRK Fusion-Positive Sarcomas: Highly Actionable Rare Alteration
NTRK1/2/3 Fusions (1-5% of Sarcomas, Varies by Subtype):
- Enriched subtypes: Infantile fibrosarcoma (>90%), congenital mesoblastic nephroma, spindle cell sarcoma
- Rare in: Adult soft tissue sarcomas (<1%)
- Larotrectinib (First-Generation TRK Inhibitor):
- Overall response rate: 75-79% in sarcomas
- Median duration of response: Not reached (>80% ongoing at 12 months)
- Progression-free survival: Median not reached
- Entrectinib (First-Generation TRK Inhibitor):
- Overall response rate: 57-63% in sarcomas
- Median duration of response: 10-21 months
- CNS activity: Crosses blood-brain barrier
- ctDNA detection: RNA-based panels required; DNA-based testing misses most fusions
- Clinical recommendation: Test all sarcomas without known driver mutations, especially pediatric cases
Integrated Genotyping Strategy
Recommended Molecular Profiling Approach:
- Initial Diagnosis: Comprehensive tissue profiling (tissue remains gold standard for sarcoma diagnosis)
- Advanced/Metastatic Disease: ctDNA genotyping when tissue unavailable or insufficient
- GIST: KIT, PDGFRA mutation panel
- Liposarcoma: MDM2 amplification, CDK4 amplification
- Unknown driver: Comprehensive DNA + RNA panel including NTRK fusions
- Treatment Monitoring: Serial ctDNA for resistance mutation detection (especially GIST on TKI therapy)
- Clinical Trial Enrollment: Genotyping identifies patients for biomarker-selected trials
Clinical Implications: Genotyping via ctDNA provides actionable information for GIST (KIT/PDGFRA mutations) and rare NTRK fusion-positive sarcomas, with dramatic treatment responses to targeted therapies. For other subtypes like leiomyosarcoma and synovial sarcoma, targeted options remain limited, though clinical trial enrollment should be considered. Tissue biopsy remains essential for sarcoma diagnosis and comprehensive profiling, with ctDNA serving as a complementary tool when tissue is unavailable or for longitudinal monitoring.
Clinical Summary & Practice Recommendations
Sarcoma ctDNA testing demonstrates highly variable clinical utility dependent on histologic subtype:
- Highest Utility - GIST: KIT/PDGFRA mutations guide imatinib/avapritinib selection (ORR 54-91%); resistance monitoring established
- Strong MRD Data - Leiomyosarcoma: 93% sensitivity with tumor-informed assay (Signatera); ctDNA kinetics correlate with treatment response
- Favorable Detection - Dedifferentiated Liposarcoma: MDM2 amplification enables copy number-based detection
- Critical for NTRK Fusions: Rare (1-5%) but highly actionable with TRK inhibitors (ORR 75-79%)
- Assay Technology Matters: Tumor-informed approaches achieve 89% overall sensitivity vs lower rates with fixed panels
- Tissue Remains Essential: ctDNA cannot replace biopsy for diagnosis or comprehensive profiling
Evidence-Based Implementation Strategy
Recommended Clinical Pathway by Subtype:
GIST (Highest Evidence):
- Initial diagnosis: KIT/PDGFRA genotyping (tissue or ctDNA)
- Treatment selection: Imatinib for KIT exon 11; dose escalation for exon 9; avapritinib for PDGFRA D842V
- MRD monitoring: Post-surgical ctDNA at 4-8 weeks, then every 3-4 months for 2 years
- Resistance surveillance: Serial ctDNA every 3 months during TKI therapy for secondary mutations
Dedifferentiated Liposarcoma:
- Diagnosis confirmation: MDM2 amplification via tissue or ctDNA
- MRD monitoring: Post-surgical ctDNA every 3-6 months (65-75% sensitivity)
- Clinical trial screening: MDM2 inhibitor trials for advanced disease
Leiomyosarcoma:
- Emerging strong evidence: Tumor-informed ctDNA achieves 93% sensitivity (Signatera)
- Consider MRD monitoring: Post-surgical ctDNA with tumor-informed assay; ctDNA kinetics correlate with treatment response
- Clinical trial enrollment: Genotyping for advanced disease trial matching
- Integration with imaging: ctDNA complements but does not replace imaging surveillance
Unknown Driver / Rare Subtypes:
- Comprehensive profiling: DNA + RNA panel including NTRK, ROS1, ALK fusions
- Clinical trial matching: Genotyping identifies biomarker-selected trial opportunities
When to Order ctDNA Testing in Sarcoma
| Clinical Indication | Recommendation | Rationale |
|---|---|---|
| GIST genotyping for treatment selection | Strongly Recommend | KIT/PDGFRA mutations guide therapy; high detection rate |
| NTRK fusion screening (unknown driver) | Consider | Rare but highly actionable; RNA-based panel required |
| Post-surgical MRD in GIST or dedifferentiated liposarcoma | Consider | 60-75% sensitivity; strong prognostic value when detected |
| Resistance monitoring during GIST TKI therapy | Consider | Detects secondary KIT mutations 1-3 months before imaging |
| Leiomyosarcoma MRD monitoring | Consider (tumor-informed) | 93% sensitivity with tumor-informed assay; emerging strong evidence from multicenter studies |
| Low-grade sarcoma surveillance | Not Recommended | <20% detection rate; clinically unreliable |
| Primary sarcoma diagnosis | Not Appropriate | Tissue biopsy mandatory for histologic classification |
Clinical Implementation: ctDNA testing in sarcoma requires a nuanced, subtype-specific approach given the extreme heterogeneity of these malignancies. Recent large-scale data (>200 patients) demonstrate that tumor-informed ctDNA assays achieve 89% overall sensitivity and 100% specificity, substantially higher than earlier estimates from smaller studies using less sensitive technologies. Leiomyosarcoma, previously considered a poor candidate for ctDNA monitoring, shows 93% sensitivity with tumor-informed approaches. GIST demonstrates the strongest evidence for genotyping and resistance monitoring. Tissue biopsy remains the gold standard for diagnosis and comprehensive molecular profiling, with ctDNA serving as a complementary tool for longitudinal monitoring. Assay technology choice (tumor-informed vs fixed panel) is a critical determinant of performance in sarcoma.
References
- Grünewald TGP et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med 2020;12:e11131.
- Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:923-934.
- Jones RL et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer 2021;145:132-142.
- Drilon A et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731-739.
- Doebele RC et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-282.
- Bill KLJ et al. Degree of MDM2 amplification affects clinical outcomes in dedifferentiated liposarcoma. Oncologist 2019;24:989-995.
- Chalmers ZR et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9:34.
- Moding EJ et al. Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS): A multicenter study. J Clin Oncol 2024;42(suppl 16):11537.
- Natera Inc. Largest sarcoma study to date with ctDNA analysis demonstrates excellent performance for Signatera. Press release, 2025.
- Klega K et al. Unlocking the potential of ctDNA in sarcomas: a review of recent advances. Cancers 2025;17(6):1040.
- Przybyl J et al. Precision medicine in diagnosis, prognosis, and disease monitoring of bone and soft tissue sarcomas using liquid biopsy: a systematic review. J Hematol Oncol 2025;18:3.
Evidence summary current through April 2026 | Version 3.0
This educational resource incorporates the latest clinical trial data for ctDNA testing in sarcoma
Related Cancer Types
Explore ctDNA and liquid biopsy evidence for related cancer types: